

Mikiya Ishihara

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6023391/publications.pdf>

Version: 2024-02-01

15
papers

321
citations

1478505

6
h-index

1058476

14
g-index

19
all docs

19
docs citations

19
times ranked

562
citing authors

#	ARTICLE	IF	CITATIONS
1	Atezolizumab-Induced Sarcoidosis-Like Reaction in a Patient with Metastatic Breast Cancer. Case Reports in Oncological Medicine, 2022, 2022, 1-4.	0.3	1
2	NY-ESO-1-specific redirected T cells with endogenous TCR knockdown mediate tumor response and cytokine release syndrome. , 2022, 10, e003811.		26
3	MAGE-A4, NY-ESO-1 and SAGE mRNA expression rates and co-expression relationships in solid tumours. BMC Cancer, 2020, 20, 606.	2.6	25
4	First-in-human phase I clinical trial of the NY-ESO-1 protein cancer vaccine with NOD2 and TLR9 stimulants in patients with NY-ESO-1-expressing refractory solid tumors. Cancer Immunology, Immunotherapy, 2020, 69, 663-675.	4.2	22
5	The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2018 edition. Breast Cancer, 2020, 27, 322-331.	2.9	47
6	CD204-positive macrophages accumulate in breast cancer tumors with high levels of infiltrating lymphocytes and programmed death ligand-1 expression. Oncology Letters, 2020, 21, 1-1.	1.8	5
7	First Case of Cytokine Release Syndrome after Nivolumab for Gastric Cancer. Case Reports in Oncology, 2019, 12, 147-156.	0.7	28
8	Tumor responses and early onset cytokine release syndrome in synovial sarcoma patients treated with a novel affinity-enhanced NY-ESO-1-targeting TCR-redirection T cell transfer.. Journal of Clinical Oncology, 2019, 37, 2530-2530.	1.6	6
9	Phase I/II clinical trial of NY-ESO-1-specific TCR-engineered T-cell transfer combined with a novel T-cell stimulator CHP:NE1 for patients with refractory soft tissue sarcoma.. Journal of Clinical Oncology, 2019, 37, TPS11074-TPS11074.	1.6	1
10	First-in-human phase I clinical trial of NY-ESO-1 protein cancer vaccine with a novel adjuvant MIS416, NOD2 and TLR9 stimulant, for patients with NY-ESO-1 expressing solid tumors.. Journal of Clinical Oncology, 2018, 36, e15176-e15176.	1.6	1
11	Pertuzumab, trastuzumab and eribulin mesylate therapy for previously treated advanced HER2-positive breast cancer: a feasibility study with analysis of biomarkers. Oncotarget, 2018, 9, 14909-14921.	1.8	6
12	PD32-05 PHASE I CLINICAL STUDY ON THE COMBINATION THERAPY OF CHP-NY-ESO-1 CANCER VACCINE AND MIS416 FOR THE TREATMENT OF PATIENTS WITH NY-ESO-1 EXPRESSING REFRACTORY UROTHELIAL CANCER OR CASTRATION-RESISTANT PROSTATE CANCER. Journal of Urology, 2016, 195, .	0.4	1
13	Colon cancer chemotherapy for a patient with CDX2-expressing metastatic thymic adenocarcinoma: a case report and literature review. International Cancer Conference Journal, 2016, 5, 113-119.	0.5	0
14	Adoptive Transfer of MAGE-A4 T-cell Receptor Gene-Transduced Lymphocytes in Patients with Recurrent Esophageal Cancer. Clinical Cancer Research, 2015, 21, 2268-2277.	7.0	139
15	Systemic CD8+ T Cell-Mediated Tumoricidal Effects by Intratumoral Treatment of Oncolytic Herpes Simplex Virus with the Agonistic Monoclonal Antibody for Murine Glucocorticoid-Induced Tumor Necrosis Factor Receptor. PLoS ONE, 2014, 9, e104669.	2.5	12